Bayram, Ece;
Batzu, Lucia;
Tilley, Bension;
Gandhi, Rhea;
Jagota, Priya;
Biundo, Roberta;
Garon, Michela;
... Weil, Rimona S; + view all
(2023)
Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?
Parkinsonism and Related Disorders
, 112
, Article 105385. 10.1016/j.parkreldis.2023.105385.
Preview |
Text
Weil_PRD rev_21mar23_RW_clean.pdf Download (244kB) | Preview |
Abstract
Background: Cognitive impairment is common in Parkinson's disease (PD) and has a substantial impact on quality of life. Despite numerous trials targeting various PD features, we still lack effective treatments for cognition beyond cholinesterase inhibitors.// Objective: To identify the gaps in recent clinical trials with cognitive outcomes in PD and consider areas for improvement. // Methods: We examined recent clinical trials with cognitive outcomes in PD registered on ClinicalTrials.gov, excluding trials without cognitive outcomes, non-interventional studies, and in atypical Parkinsonian disorders. Included trials were categorized by treatment approach (investigational medicinal product, behavioral, physical activity, device-based). Details of trial design and outcomes were collected. // Results: 178 trials at different stages of trial completion were considered. 46 trials were completed, 25 had available results. Mean follow-up duration was 29.9 weeks. Most common cognitive measure was Montreal Cognitive Assessment. Most were performed in North America or Europe. Majority of the participants identified as non-Hispanic and White. Only eight trials showed improvement in cognition, none showed improvement beyond four months. These included trials of international medicinal products, cognitive and physical interventions and devices. GRADE certainty levels ranged from Moderate to Very Low. Only mevidalen had a Moderate certainty for potential clinical effectiveness. // Conclusions: Amongst a large number of trials for cognition in PD, only a small proportion were completed. Few showed significant improvement, with no proven long-lasting effects. Trial design, lack of enrichment for at-risk groups, short follow-up duration, insensitive outcome measures likely contribute to lack of detectable benefit and should be considered in future trials.
Archive Staff Only
 |
View Item |
